1. Home
  2. IMNM vs SYRE Comparison

IMNM vs SYRE Comparison

Compare IMNM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.58

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$41.11

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
SYRE
Founded
2006
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.6B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
IMNM
SYRE
Price
$22.58
$41.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
7
Target Price
$32.10
$55.57
AVG Volume (30 Days)
959.3K
681.3K
Earning Date
01-01-0001
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$11.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.15
$10.91
52 Week High
$27.65
$45.76

Technical Indicators

Market Signals
Indicator
IMNM
SYRE
Relative Strength Index (RSI) 49.44 60.56
Support Level $18.98 $14.62
Resistance Level $27.14 $45.76
Average True Range (ATR) 1.11 2.38
MACD -0.11 0.07
Stochastic Oscillator 45.25 61.79

Price Performance

Historical Comparison
IMNM
SYRE

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: